| Overview |
| bs-7602R |
| TIAF1 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TIAF1 |
| 34-115/115 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 9220 |
| Nucleus |
| MAJN; TGFB1 induced anti apoptotic factor 1 12 kDa TGF beta1 induced antiapoptotic factor; TGFB1 induced anti apoptotic factor 1; TIAF1_HUMAN. |
| TIAF-1 (TGF Beta 1-induced antiapoptotic factor 1), also known as MYO18A, MAJN or MYSPDZ, is a TGF Beta 1-induced anti-apoptotic factor that localizes to the nucleus and functions to inhibit the cytotoxic effects of TNF? TRADD and FADD. Two isoforms of mouse TIAF-1 exist and are designated MysPDZ-Alpha and MysPDZ-Beta. MysPDZ-Alpha consists of a KE-rich region, an N-terminal PDZ domain and a prevalent myosin homologous head region, while the MysPDZ-Beta isoform lacks the KE-rich region and PDZ domain. MysPDZ-Alpha is present in most tissues and is known to co-localize with the ER-Golgi complex and with membrane ruffles and filopodia. MysPDZ-Beta is expressed specifically in hematopoietic tissues and cell lines and shows dispersed localization in the cytoplasm. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz